Research Report on China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2014-2018
|出版商||China Research and Intelligence||商品編碼||288686|
|出版日期||內容資訊||英文 50 Pages
|中國的豬隻繁殖、呼吸障礙症候群(PRRS)疫苗產業分析 Research Report on China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2014-2018|
|出版日期: 2014年09月17日||內容資訊: 英文 50 Pages||
China is the world's largest producer and consumer of pork with the output volume of pork accounting for nearly 50% of the total. The output volume of pork was 54.93 million tons in China in 2013, up by 2.8% YOY. The livestock volume of pigs was 474.11 million, down by 0.4% YOY while the stock volume of fattened pigs was 715.57 million, up by 2.5% YOY.
The PRRS broke out in southern China and spread rapidly nationwide after summer in 2006, which lead to increases in mortality rate of piglets and pork prices and significant decrease in output volume of pork. In May 2007, the Ministry of Agriculture of China approved the production of highly-pathogenic porcine reproductive and respiratory syndrome inactivated vaccine (NVDC-JXA1) in six manufacturers of biological products. Porcine reproductive and respiratory syndrome (PRRS) remains one of the key compulsory immunity diseases in China.
According to National Compulsory Immunization Plan of Animal Epidemic Diseases in 2014 issued by Ministry of Agriculture of China, the government conducts compulsory immunizations against 4 diseases, including highly-pathogenic PRRS. The government is responsible for the expenses. Currently highly pathogenic PRRS vaccines are purchased by the government through invitation for bidding in China.
The market competition is intensive in the PRRS vaccine industry in China. There are 26 manufacturers of PRRS vaccines in China, including Dahuanong, Xinjiang Tecon Animal Husbandry Bio-Technology Co., Ltd., Qingdao Yebio Bioengineering Co., Ltd. and Inner Mongolia Jinyu Group Stock Company. In terms of the direct sales of high-end vaccines, the PRRS vaccines of Zoetis went to the market in Guangzhou at the end of August 2013 after Boehringer. These foreign-funded vaccine brands occupy the market shares using the brand advantages, which intensify the market competition.
As Chinese economy develops and the living standards increase, the demand for pork will continue to grow, which promotes the development of pig raising industry. The market size of PRRS vaccines will continue to increase in China in the next few years, which attract many animal health enterprises' attention.
Through this report, the readers can acquire the following information:
The Following Enterprises and People Are Recommended to Purchase This Report: